Introduction
One year ago, the first version of Immuno-T, a motion comic explaining to patients and caregivers how immunotherapy strategies work, was released. People were informed on and inspired to use the application during (inter)national meetings and events for the general public. Meanwhile, the motion comic was further refined and adapted into a second version, based on the evaluations we’ve collected on the first version. Adaptations included a multilanguage tool (currently 6 languages), increased user friendliness, and a new supporting musical score. Also, a website was launched from which the second version could be downloaded on tablet or smartphone (both android and iOS) and a new online evaluation form could be filled in. In 10 months 40 people have evaluated the motion comic online, and these results are presented here, as well as our future plans within the Immuno-T program.

Methods
A total of 47 participants have evaluated the motion comic through an online questionnaire. 42 participants (from Belgium, n=39, and the Netherlands, n=3) evaluated the Dutch version, and 5 Belgian participants evaluated the French version.

Results
As shown in Figure 1, the total group (n=47) consisted of patients (n=15) and their families (n=2), general public (n=11), students (n=7), health care professionals (n=5), researchers (n=5) and kindergarten teachers (n=2). Participants’ age ranged from 19 to 80 years, with a even distribution between the different generations. The majority of the evaluators (95,7%, n=45) thought the motion comic is a good way to explain immunotherapy to patients. 24 individuals (51,1%) felt mainly interested after watching immuno-T, and a total of 34 participants (72,3%) felt hopeful or motivated (Figure 2). 
Focusing on the patient group (n=15), all of the responders think the Immuno-T motion comic is a good tool to use in a patient-doctor consultation. 11 patients (73,3%) felt hopeful and/or motivated after watching the whole motion comic, while 3 of them (20%) felt combative and 5 (33,3%) felt gripped and intrigued. 
As for the new musical score,  35 participants (77,7%) think the music is suitable for the app, while 6 evaluators (13,3%) think the new music is not or not at all fitted to support the motion comic.

Conclusion and perspectives
The detailed evaluations allow us  to further improve Immuno-T, and aid us in the development of other motion comics we plan to release under the Cancer-T in motion umbrella. 
With the current version of Immuno-T, a single-center pilot study is being set up, to test the efficacy and usability of Immuno-T, based on qualitative research during the experience of the tool, and using validated questionnaires. With this study we want to evaluate the impact of Immuno-T on patient’s understanding of the disease and its treatment, patient empowerment and the decision making process. The study protocol is added in Figure 3.

Immuno-T, 1 year into the motion comic: where we stand, and where we’re heading